Bank of New York Mellon Corp - ROCKET PHARMACEUTICALS INC ownership

ROCKET PHARMACEUTICALS INC's ticker is RCKT and the CUSIP is 77313F106. A total of 98 filers reported holding ROCKET PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 10.32 and the average weighting 0.3%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of ROCKET PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,004,724
+25.6%
244,252
+21.8%
0.00%0.0%
Q2 2023$3,983,895
+12.9%
200,498
-2.7%
0.00%0.0%
Q1 2023$3,529,928
-4.8%
206,067
+8.8%
0.00%0.0%
Q4 2022$3,707,889
+54.1%
189,468
+25.7%
0.00%0.0%
Q3 2022$2,406,000
+26.9%
150,731
+9.4%
0.00%
Q2 2022$1,896,000
-8.0%
137,825
+6.1%
0.00%
Q1 2022$2,060,000
-27.2%
129,889
+0.2%
0.00%
-100.0%
Q4 2021$2,828,000
-42.8%
129,581
-21.7%
0.00%0.0%
Q3 2021$4,946,000
-29.0%
165,473
+5.2%
0.00%0.0%
Q2 2021$6,967,000
+3.1%
157,309
+3.3%
0.00%0.0%
Q1 2021$6,755,000
-19.9%
152,251
-1.0%
0.00%
-50.0%
Q4 2020$8,435,000
+187.8%
153,804
+19.9%
0.00%
+100.0%
Q3 2020$2,931,000
+7.6%
128,229
-1.5%
0.00%0.0%
Q2 2020$2,725,000
+58.8%
130,232
+5.9%
0.00%0.0%
Q1 2020$1,716,000
-36.4%
122,980
+3.7%
0.00%0.0%
Q4 2019$2,698,000
+102.9%
118,549
+3.9%
0.00%
Q3 2019$1,330,000
-26.0%
114,144
-4.8%
0.00%
Q2 2019$1,798,000
+7.2%
119,842
+25.3%
0.00%
Q1 2019$1,678,000
+27.0%
95,637
+7.3%
0.00%
Q4 2018$1,321,000
-31.6%
89,159
+13.7%
0.00%
Q3 2018$1,930,000
+39.6%
78,395
+11.3%
0.00%
Q2 2018$1,383,000
+564.9%
70,451
+534.9%
0.00%
Q1 2018$208,00011,0970.00%
Other shareholders
ROCKET PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
M28 Capital Management LP 665,880$10,627,00011.09%
RTW INVESTMENTS, LP 15,802,802$252,213,0005.82%
Ally Bridge Group (NY) LLC 479,506$7,653,0005.05%
TANG CAPITAL MANAGEMENT LLC 1,265,900$20,204,0002.48%
TIGER MANAGEMENT L.L.C. 279,700$4,464,0001.95%
Prosight Management, LP 200,000$3,192,0001.71%
COWEN AND COMPANY, LLC 999,588$15,953,0001.53%
Boxer Capital, LLC 1,466,051$23,398,0001.32%
Affinity Asset Advisors, LLC 267,794$4,274,0001.19%
HARBOR CAPITAL ADVISORS, INC. 66,410$1,060,0000.97%
View complete list of ROCKET PHARMACEUTICALS INC shareholders